Biovie (BIVI) Non Operating Income (2022 - 2026)
Biovie (BIVI) posted Non Operating Income of $115078.0 for Q1 2026, down 40.32% sequentially from $192830.0 in Q4 2025, and down 42.4% YoY from $199786.0 in Q1 2025.
Biovie (BIVI) Non Operating Income (2022 - 2026) Analysis & Trends
Biovie has reported Non Operating Income for 5 years, with the latest figure at $115078.0 in Q1 2026.
- Quarterly Non Operating Income fell 42.4% year-over-year to $115078.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $678890.0 (up 240.05% YoY) and the FY2025 annual result came in at $524080.0, up 787.49% from the prior year.
- Non Operating Income slipped to $115078.0 in Q1 2026 per BIVI's latest filing, from $192830.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $1.9 million in Q2 2023 and troughed at -$4.2 million in Q4 2022.
- A 5-year average of -$178994.2 and a median of $169650.5 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income slumped 118.11% in 2024, then soared 757.89% in 2025.
- Over 5 years, Non Operating Income stood at -$4.2 million in 2022, then surged by 109.06% to $379963.0 in 2023, then slumped by 52.55% to $180300.0 in 2024, then climbed by 6.95% to $192830.0 in 2025, then sank by 40.32% to $115078.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $115078.0, $192830.0, and $197038.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | 73,924.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73,924.00 |
| Mar 31, 2026 | 115,078.00 |
| Dec 31, 2025 | 192,830.00 |
| Sep 30, 2025 | 197,038.00 |
| Jun 30, 2025 | 173,944.00 |
| Mar 31, 2025 | 199,786.00 |
| Dec 31, 2024 | 180,300.00 |
| Sep 30, 2024 | -29,950.00 |
| Jun 30, 2024 | -150,494.00 |
| Mar 31, 2024 | -335,775.00 |
| Dec 31, 2023 | 379,963.00 |
| Sep 30, 2023 | 165,357.00 |
| Jun 30, 2023 | 1.86 Mn |
| Mar 31, 2023 | -1.27 Mn |
| Dec 31, 2022 | -4.19 Mn |